Ocugen, Inc. (Ocugen) filed a Form 8-K on October 15, 2026, to disclose an updated investor presentation. The document, filed under Regulation FD, provides an overview of the company's strategy and clinical pipeline, specifically focusing on its gene therapy platform and the status of its lead product candidate, OCU400.
The presentation outlines Ocugen’s goal to submit three Biologics License Applications (BLAs) by 2028. The company is targeting three specific indications: Stargardt Disease, Advanced dry age-related macular degeneration (dAMD), and Retinitis Pigmentosa (RP). For Stargardt Disease, the company reports that a Phase 2/3 pivotal confirmatory clinical trial is in progress and enrollment has been completed. For dAMD, the Phase 3 trial was initiated in the third quarter of 2026. Regarding Retinitis Pigmentosa, the company states that the Phase 3 trial is in progress and enrollment has been completed.
The presentation details the clinical development of OCU400, a gene-agnostic therapy designed to treat Retinitis Pigmentosa. The company notes that the Phase 3 liMeLiGhT trial is the largest orphan gene therapy clinical trial ever run, with 140 patients enrolled. The primary endpoint for this trial is a 12-month change in visual function via a Low Luminance Visual Acuity (LLVA) scale. The company projects that 71.4% of treated eyes will meet the primary endpoint of a 2 lux level improvement from baseline.
Regarding safety data, Ocugen reports that OCU400 was generally safe and well tolerated through three years of follow-up, with no serious adverse events (SAEs) related to the treatment. The company states that 88% of evaluable treated subjects showed improvement or preservation of LLVA compared to untreated eyes at Year 3.
In terms of regulatory milestones, the company anticipates top-line clinical readouts in the first half of 2027, followed by a U.S. BLA filing in the second quarter of 2027. The company also highlights a partnership with Kwangdong Pharmaceutical, which includes potential sales milestones of up to $180 million and royalties equal to 25% of net sales.
Additionally, the presentation notes a regulatory approval for OCU400 from the Bahamas Regulatory Agency (LARTA). This approval provides provisional approval and priority designation, with full approval expected within 90 days under a regulated Early Access Program (EAP). The company states that the EAP is open to patients globally at commercial pricing and expects to generate revenue from the program.
